Synopsis
Axial Therapeutics is revolutionising the treatment of neurological diseases and disorders by utilising cutting-edge science in the gut-brain axis.
By identifying specific bacteria and their by-products in the gut that are connected to the progression, symptoms and pathology of neurodegenerative diseases and neurodevelopmental disorders, Axial is able to pinpoint new targets for therapeutics in the gut microbiome.
Based on these new targets, Axial focuses on creating small molecule therapies with well-defined mechanisms of action that can reduce the impact of these bacteria and their by-products. This gut-targeted, localised approach to small molecule therapeutics represents a new era in microbiome-inspired treatments for neurological conditions.
